July 27, 2020 -- Immunic has enrolled the first patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase (DHODH) inhibitor, in combination with the neuraminidase inhibitor oseltamivir (Tamiflu).
The prospective, randomized, parallel-group, open-label phase IIB study will evaluate the safety of IMU-838 in approximately 120 adult patients with moderate to severe COVID-19 symptoms at University Hospitals Coventry and Warwickshire National Health Service Trust in the U.K. The company believes that there is a synergistic effect between direct antiviral drugs such as oseltamivir and DHODH inhibitors.
In preclinical studies IMU-838 has been shown to inhibit replication of SARS-CoV-2 with an attractive pharmacokinetic safety and tolerability profile. To date, the drug has been tested in around 650 individuals.
IMU-838 is also undergoing phase II trials in patients with COVID-19, ulcerative colitis, and relapsing-remitting multiple sclerosis, where top-line data is expected in the first half of August 2020.
Copyright © 2020 scienceboard.net